Novel Agents in Chronic Lymphocytic Leukemia: New Combination Therapies and Strategies to Overcome Resistance

SIMPLE SUMMARY: Nowadays, many patients with chronic lymphocytic leukemia (CLL) are treated with so-called novel agents, including BTK inhibitors, Bcl-2 inhibitors and PI3K inhibitors. As CLL is a chronic disease, most patients will relapse on or after treatment with these drugs and various mechanis...

Descripción completa

Detalles Bibliográficos
Autores principales: Fürstenau, Moritz, Eichhorst, Barbara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8002361/
https://www.ncbi.nlm.nih.gov/pubmed/33809580
http://dx.doi.org/10.3390/cancers13061336

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8002361/
https://www.ncbi.nlm.nih.gov/pubmed/33809580
http://dx.doi.org/10.3390/cancers13061336

Ejemplares similares